Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2022 | New diagnostic criteria for apathy in neurocognitive disorders

Krista Lanctôt, PhD, University of Toronto, Toronto, ON, Canada, discusses the newly established diagnostic criteria for apathy which are paving the way for future clinical trials looking at apathy in dementia. The recently published criteria for the diagnosis of major and minor neurocognitive disorders were decided by representatives from academia, healthcare, industry, and regulatory bodies, including members of the NPS-PIA, who agreed on consensus criteria to diagnose clinically significant apathy in neurocognitive disorders. This diagnosis is based on diminished interest, diminished initiation, and diminished emotional responsiveness/expression. Together, this updates previous diagnostic criteria by utilizing knowledge of the neural circuitry which underlies apathy, particularly that there is different neural circuitry for initiative, interest, and emotional blunting. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.


Dr Lanctôt gratefully acknowledges support from the Canadian Institutes of Health Research (PJ2-179753, PJT-183584), Pooler Charitable Fund, Canadian Consortium for Neurodegeneration in Aging (CNA 163902), Alzheimer’s Association Part the Cloud (PTCG-20-700751, PTC-18-543823), Weston Foundation (CT190002), and Alzheimer’s Drug Discovery Foundation (201808-2016354). Consultant or Advisory Board: BioXcel Therapeutics, Cerevel Therapeutics, Eisai Co., Ltd., ICG Pharma, Jazz Pharmaceuticals, Kondor Pharma, H LundbeckA/S, Merck Sharp Dohme, Novo Nordisk, Praxis Therapeutics, Sumitomo.